Drug Approval | June 08, 2023
European Commission authorises GSK’s Arexvy for older adults
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
The new Biolys provides higher concentration of L-lysine
Debut Biotechnology has outstanding enzyme search and design technology and a bio-manufacturing platform (precision fermentation, cell-free synthesis) using those enzymes
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Subscribe To Our Newsletter & Stay Updated
